Abstract

Background

Pegylated liposomal doxorubicin (PLD) is a liposome-encapsulated form of doxorubicin with equivalent efficacy and less cardiotoxicity. This phase 2 study evaluated the efficacy and safety of the PLD-containing CHOP regimen in newly diagnosed patients with aggressive peripheral T-cell lymphomas (PTCL).

Methods

Patients received PLD, cyclophosphamide, vincristine/vindesine, plus prednisone every 3 weeks for up to 6 cycles. The primary endpoint was the objective response rate at the end of treatment (EOT).

Results

From September 2015 to January 2017, 40 patients were treated. At the EOT, objective response was achieved by 82.5% of patients, with 62.5% complete response. As of the cutoff date (September 26, 2023), median progression-free survival (mPFS) and overall survival (mOS) were not reached (NR). The 2-year, 5-year, and 8-year PFS rates were 55.1%, 52.0%, and 52.0%. OS rate was 80.0% at 2 years, 62.5% at 5 years, and 54.3% at 8 years. Patients with progression of disease within 24 months (POD24) had worse prognosis than those without POD24, regarding mOS (41.2 months vs NR), 5-year OS (33.3% vs 94.4%), and 8-year OS (13.3% vs 94.4%). Common grade 3-4 adverse events were neutropenia (87.5%), leukopenia (80.0%), anemia (17.5%), and pneumonitis (17.5%).

Conclusion

This combination had long-term benefits and manageable tolerability, particularly with less cardiotoxicity, for aggressive PTCL, which might provide a favorable benefit-risk balance.

ClinicalTrials.gov Identifier

Chinese Clinical Trial Registry, ChiCTR2100054588; IRB Approved: Ethics committee of Fudan University Shanghai Cancer Center (Date 2015.8.31/No. 1508151-13.

Details

Title
Phase 2 study of pegylated liposomal doxorubicin plus cyclophosphamide, vincristine/vindesine, and prednisone in newly diagnosed PTCL: 8-year results
Author
Zu-Guang Xia 1 ; Fang-Fang, Lv 1 ; Zhang, Qun-Ling 1 ; Yi-Zhen, Liu 1 ; Sheng-Jian, Zhang 2 ; Liu, Chang 2 ; Xiao-Qiu, Li 2 ; Yu, Wen 3 ; Zhen-Yu, Wu 3 ; Xiao-Nan, Hong 1 ; Guo, Ye 4 ; Jun-Ning Cao 1 

 Department of Medical Oncology, Fudan University Shanghai Cancer Center , Shanghai, People’s Republic of China 
 Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, People’s Republic of China 
 Department of Biostatistics, School of Public Health, Key Laboratory of Public Health Safety and Collaborative Innovation Center of Social Risks Governance in Health, Fudan University , Shanghai, People’s Republic of China 
 Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine , Shanghai, People’s Republic of China 
Pages
819-e1223
Publication year
2024
Publication date
Sep 2024
Publisher
Oxford University Press
ISSN
10837159
e-ISSN
1549490X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3191889763
Copyright
© The Author(s) 2024. Published by Oxford University Press. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.